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Abstract 
Background & Aims 
To undertake the first randomised controlled trial to evaluate the effectiveness of a brief 
intervention delivered by community pharmacists to reduce hazardous or harmful drinking. 
Design 
This parallel group individually randomised trial, allocated participants to brief alcohol 
intervention (n=205) or a leaflet-only control condition (n=202), with follow-up study after 3 
months. 
Setting 
16 community pharmacies in one London borough, UK. 
Participants 
407 pharmacy customers (aged 18 or over) with AUDIT scores 8-19 inclusive. 
Intervention 
A brief motivational discussion of approximately 10 minutes duration for which 17 
pharmacists received a half-day of training. 
Measurements  
Hazardous or harmful drinking was assessed using the Alcohol Use Disorders Identification 
Test (AUDIT) administered by telephone by a researcher blind to allocation status. The two 
primary outcomes were: 1) change in AUDIT total scores and 2) the proportions no longer 
hazardous or harmful drinkers (scoring <8) at three months. The four secondary outcomes 
were: the three sub-scale scores of the AUDIT (for consumption, problems and 
dependence), and health status according to the EQ-5D (a standardised instrument for use 
as a measure of health outcome). 
Findings  
At 3 months 326 (80% overall; 82% intervention, 78% control) participants were followed up. 
The difference in reduction in total AUDIT score (intervention minus control) was -0.57 95% 
CI -1.59 to 0.45, p = 0.28. The odds ratio for AUDIT ˂8 (control as reference) was 0.87 95% 
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CI 0.50 to 1.51, p = 0.61). For two of the four secondary outcomes (dependence score: -0.46 
95% CI -0.82 to -0.09, p = 0.014; health status score: -0.09 95% CI -0.16 to -0.02, p = 0.013) 
the control group did better, and in the other two there were no differences (consumption 
score: -0.05 95% CI -0.54 to 0.44, p = 0.85; non-dependence problems score: -0.13 95% CI 
-0.66 to 0.41). Sensitivity analyses did not change these findings.   
Conclusions 
A brief intervention delivered by community pharmacists appears to have had no effect in 
reducing hazardous or harmful alcohol consumption. 
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Introduction  
Alcohol use has been identified as the cause of approximately 3.3 million deaths  
worldwide every year, approximately 5.9% of all deaths (1). In the UK alcohol costs society 
£25.1 billion per annum, with National Health Service costs £2.7 billion and is the third 
leading cause of ill health (2). Reducing alcohol problems requires public policies to increase 
price, limit the accessibility of alcohol and challenge the social acceptability of heavy drinking 
(3). These policies can be supported by individual-level interventions to help people who 
drink heavily to reduce their alcohol intake. Brief alcohol interventions typically involve 
discussion with a health professional to help people reflect on their drinking and encourage 
self-directed behaviour change. There is strong support for the efficacy of brief interventions 
(BI) in reducing alcohol consumption in primary care settings (4). The World Health 
Organisation (5) has recommended widespread implementation of BI for hazardous and 
harmful drinkers across healthcare settings. The UK Department of Health has 
recommended that pharmacy based BI should be piloted and evaluated as part of the 
developing public health function of community pharmacies (6). 
 
Pharmacists and pharmacy staff are the third largest professional health workforce in the 
world after nurses and doctors (7, 8). In recent years UK community pharmacy practice has 
developed to include extended roles for pharmacy staff (9). Pharmacies now offer a range of 
services designed to promote and protect public health, including medication use reviews, 
sexual health screening and smoking cessation. Most pharmacies now have consultation 
rooms to allow private discussions. There has also been the recent introduction of Healthy 
Living Pharmacies (10), where pharmacy teams actively engage with local communities and 
other health professionals. Development of services within pharmacies is thus a UK national 
priority for public health (6). This study was informed by a series of pre-trial studies (11-13), 
and tests the primary hypothesis that brief alcohol intervention delivered by community 
pharmacists is effective at reducing hazardous or harmful drinking among pharmacy 
5 
 
customers at three-month follow-up compared to a non-intervention leaflet-only control 
condition. 
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Method 
The study is a parallel group randomised controlled trial conducted in 16 community  
pharmacies within the London borough of Hammersmith and Fulham, UK from May 2012 to 
May 2013. This borough has a population of 177100, which comprises a high proportion of 
young adults and is ethnically diverse (14). Local needs assessment suggests that 
Hammersmith and Fulham residents have the highest rates of high risk drinking  in London 
(14). This study was ethically approved by the NRES Committee London and The West 
London Primary Care Consortium (for Research and Innovation) and a detailed account of 
the methods is available in the published protocol(15).   
 
Sample size 
Sample size consideration was originally based on a meta analytic effect size of 0.30 found 
on composite outcome measures in non-treatment seeking samples across settings at three-
month follow-up in a previous review(16). In a one sided test a sample of 139 participants 
would be needed in each group to detect an effect of this magnitude on the AUDIT (17), 
assuming 80% power and a significance level of 5%. Generously allowing for 30% attrition at 
three months, 199 participants per group were required by the power calculation.  
 
Findings from previous studies (11, 12, 18, 19) provided information on potential numbers of 
people who could be approached, the proportion of people who were risky drinkers based on 
a single question, and numbers screened positive who might agree to participate.  We 
estimated that for every 15 customers approached initially, one customer would meet the 
criteria for entry into the study and agree to participate. 
 
Participants and recruitment  
All 40 community pharmacies with an NHS contract within the London Borough of 
Hammersmith and Fulham were invited to participate, with a requirement that the pharmacy 
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had a consultation room. Eligible trial participants were those aged 18 years or over who 
accessed services within the 16 participating community pharmacies who: a) had AUDIT 
scores 8-19 inclusive; b) were contactable by phone during the study; c) had a home 
address in the UK; and d) were able to speak, read and write in English; and d) were able to 
give informed consent.  Exclusion criteria were: a) currently in treatment for alcohol 
problems; b) currently involved in other alcohol research; c) an employee of a pharmacy 
involved in the trial.  
 
Pharmacy customers exhibiting one or more of the following behaviours were identified as 
potential participants by pharmacy staff: a) viewing study posters and flyers displayed within 
the pharmacy area; b) making a general health query or seeking advice linked to alcohol 
use; c) purchasing pharmacy over the counter products for smoking cessation aids, 
gastrointestinal remedies, sleep aids and central nervous system depressants (listed in the 
Medicine Chest directory) (20); d) receiving any of the following pharmacy services: smoking 
cessation, medication use review, health check or emergency hormonal contraception; e) 
presenting prescriptions for medications for any of the following conditions: cardiovascular 
disease, depression or anxiety, diabetes or gastric problems. 
 
These customers were offered a copy of the participant information sheet by pharmacy 
support staff and invited to be screened for eligibility for the study. The number of customers 
informed about the study but who declined to be screened for eligibility was recorded as was 
anonymous information on customers’ gender, activity in the pharmacy, reason given for not 
participating and the date. Customers who were willing to be screened were asked “How 
often do you have three or more drinks on a single occasion?” Those drinking this amount 
monthly or more frequently were invited to the second stage of the screening process, with 
the AUDIT administered by the pharmacist in the consultation room. Those who agreed 
provided formal consent to participate. Customers who scored ≥ 20 on the AUDIT were 
potentially dependent drinkers who were given a letter with their AUDIT result, advised to 
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take it to their GP, with an offer also to book an appointment with, and fax a letter to their 
GP. Customers identified as low risk drinkers (AUDIT ≤ 7) were also excluded from the 
study. Both excluded groups were given, “Units and You” booklet (21), a “Unit/Calorie 
Calculator Wheel”(22) and a leaflet listing alcohol services.  
 
Consenting participants scoring 8-19 inclusive on the AUDIT were recruited and had data 
(i.e. age, gender, ethnicity, education, place of residence, being diagnosed with, or 
prescribed medications for, cardiovascular disease, depression/anxiety, diabetes or gastric 
problems) recorded at baseline by the community pharmacist who entered these details 
directly into a secure online recording system (23). 
 
Randomisation and blinding 
We estimated that each pharmacist would recruit 24 participants on average over a period of 
6 months, with 1:1 randomisation stratified within each of the 17 participating pharmacists. 
The random sequence was generated by the first author in Excel in blocks of 12, with further 
blocks of the same size generated for those who recruited more participants. Allocation 
status was revealed only after pharmacists opened a sealed numbered envelope. Thereafter 
pharmacists were not involved in research data collection. Pharmacists received training on 
the importance of following trial procedures including allocation concealment. Possible 
subversion of randomisation was monitored by regular checking of sealed envelopes for 
evidence of tampering during visits and numerical ordering on the online data entry system. 
For the purposes of both follow-up study and data management, relevant personnel were 
blinded to randomisation status throughout the trial. 
 
Interventions 
Participants allocated to BI were offered a discussion with the pharmacist of up to 10 
minutes duration (24). The purpose of the BI was to encourage participants to think further 
about their drinking and whether they should reduce it, and discuss how if they were ready to 
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do so. The intervention contained a number of structured components in the form of an 
intervention protocol (see online appendix). The conversation began by the pharmacist 
building rapport through asking questions about their experience of answering the AUDIT 
questions. Participants were then encouraged to talk about how drinking fitted in with their 
lives, explore any ambivalence and elicit their evaluation of their drinking including any 
associated problems. The conversation was closed by either the participant or the 
pharmacist providing a summary of the conversation. Participants were also given the “Units 
and You” booklet(21), a “Unit/Calorie Calculator Wheel” (22) and an alcohol services leaflet. 
 
All trial pharmacists had been trained over 3.5 hours to deliver the intervention protocol 
including flexible use of these discussion topics in ways influenced by the counselling 
approach of motivational interviewing (25). In such a brief training workshop it was not 
feasible to aim to train the pharmacists in motivational interviewing as this approach requires 
ongoing supervision to learn it. A two hour evening follow-up training session was arranged 
seven weeks after the start of the trial to address challenges and share learning across the 
group, and was attended by 10 pharmacists. 
 
Participants allocated to the control condition were not informed they were control 
participants, and immediately after the envelope was opened were given a leaflet by the 
pharmacist. This was, entitled “Alcohol: The Basics” and included information about alcohol 
not expected to be effective at promoting behaviour change (26). 
 
Outcome evaluation 
Outcomes were assessed using the AUDIT administered by telephone by a researcher blind 
to allocation status The primary outcomes were change in total AUDIT scores from 
recruitment to follow-up 3 months later, and the proportions remaining hazardous or harmful 
drinkers (scoring 8 or higher on AUDIT) at follow-up. Secondary outcomes were change in 
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AUDIT subscales scores (for alcohol consumption, problems, and dependence), and general 
health status assessed using the EQ-5D(27) at follow-up.  
 
Statistical methods 
Loss to follow-up was assessed using Pearson χ2 (intervention or control, gender, ethnicity 
and education) and independent groups t-test (Age, AUDIT baseline and sub-scale scores). 
We followed the intent-to-treat (ITT) principle in accordance with an a priori statistical 
analysis plan. The primary analysis was specified as complete cases only. A sensitivity 
analysis was performed on the two primary outcomes whereby the baseline value was 
carried forward to investigate the impact of attrition. To ascertain whether non-response at 3 
months was related to randomised group a Pearson χ2 test was performed. Between group 
differences in AUDIT scores at follow-up were tested using a GLMM with fixed effects for 
baseline score and group, and random intercepts for pharmacist (n=17 in 16 pharmacies, 
closely matched). Fixed effects for gender, age, ethnicity (grouped into Black Minority Ethnic, 
White British, and any other white background) and education (degree or equivalent, 
continuing education but not to degree level, and no continuing education) were then added 
to this model. The moderating effect of each of these prognostic variables was tested by 
adding the interaction between each moderating and group variable to the model (total 
AUDIT score only). Histograms of the residual and Q-Q plots were inspected to make sure 
that the model assumptions were being met. A wild Bootstrap analysis was performed on the 
total AUDIT and sub-scale score models to assess the effect of potential violations to the 
model assumptions (28). For the binary primary outcome a generalised logistic mixed 
regression model was used to test the effect of randomised group using the same approach, 
except that baseline value was not included in the model because everyone was ≥ 8 at study 
entry. Within group changes in AUDIT scores from baseline to follow-up were tested using a 
generalised linear mixed model (GLMM) with fixed effects for group and time (nested within 
group) and random effects for pharmacist and participant (nested within pharmacist).  All the 
statistical analyses were performed using IBM SPSS Version 22 (29).  
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Results 
Recruitment and follow-up 
Of the 2361 pharmacy customers who were approached, 561 (24%) were interested in 
participating, of whom 549 passed the first stage single question screen (see CONSORT 
flowchart in Figure 1). From this group 541 consented to participate and were administered 
the AUDIT. A further 134 were excluded; 94 (17%) were identified as a low risk drinkers 
(AUDIT ≤ 7); 38 (7%) as possible dependent drinkers (AUDIT ≥ 20); and 2 (0.4%) had 
incomplete data recorded by the pharmacist. The remaining 407 were randomised; 205 to 
intervention, 202 to control. At 3 months outcomes were collected from 80% of those 
randomised (n=326, see Figure 1). Loss to follow-up was similar in control or intervention 
groups (22% vs. 18% p=0.39). It varied only by age (responder 42.1 (SD 17.1) vs. non-
responder 32.0 (SD 12.2 p<0.001) and AUDIT consumption score (responder 8.25 (SD 1.52) 
vs. non-responder 7.77 (SD 1.60) p=0.011). 
 
Baseline characteristics 
The socio-demographic characteristics are presented in Table 1 (see Table 1a online 
information for the characteristics of only those who completed follow-up). The ethnic 
diversity of trial participants reflected the ethnic backgrounds of residents from the inner 
London Borough of Hammersmith and Fulham (30). Information on the pharmacists and the 
pharmacies is presented in Tables 1b-1c (online information). 
 
Primary outcomes 
The AUDIT total score did not differ significantly between the two groups and did not change 
significantly between baseline and follow-up in either the intervention or control group (Table 
2). The sensitivity analysis, carrying baseline values forward for people with missing follow-
up scores produced similar outcomes (Unadjusted: 0.49 95% CI -1.33 to 0.36; Adjusted: -
0.37, -1.18 to 0.45).The Bootstrap estimate for mean difference from the adjusted model was 
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very similar (-0.57 95% CI -1.62 to 0.46 p=0.32). None of the prognostic variables used in 
the adjusted model had any moderating effect on total AUDIT score at follow-up (p=0.22 to 
0.46). 
 
The odds ratio (OR) for the effect of the intervention upon the binary primary outcome was 
not statistically significant either in the unadjusted or adjusted models and this result was 
confirmed by the sensitivity analysis (Unadjusted OR 0.87, 0.53 to 1.42; Adjusted OR 0.95, 
0.55 to 1.63). 
 
Secondary outcomes 
For secondary outcomes, AUDIT consumption sub-scale score did not differ significantly 
between groups but reduced significantly in both the intervention and control groups (see 
Table 2). The dependence sub-scale score differed significantly between groups at follow-up 
in both GLMMs (Table 2) but only decreased significantly, from baseline to follow-up, in the 
control group. The AUDIT problems sub-scale score did not differ significantly between 
groups and but did increase significantly from baseline to follow-up in the intervention group 
(Table 2). The bootstrap estimates for difference between groups and 95% confidence 
intervals for the three AUDIT sub-scale scores were very similar to those produced from the 
GLMMs. General health (EQ-5D) at follow-up was significantly better in the control 
compared to the intervention group in both the unadjusted and adjusted models. There were 
no adverse events reported by participants that were considered to be related to 
participation in the trial. 
 
When participants were asked if they recalled having a discussion with the pharmacist about 
their drinking following the AUDIT questions, only 39% (n = 62) of control participants 
correctly responded, i.e. the majority reported that they had such a discussion. By 
comparison, 77% (n= 130) of intervention participants correctly reported they had a 
discussion about their drinking with the pharmacist.   
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Discussion 
This randomised controlled trial was designed to determine if brief alcohol interventions 
delivered by community pharmacists were effective in reducing hazardous and harmful 
drinking amongst customers after three months in comparison with a leaflet only control 
condition. It found no evidence of effectiveness, with the two statistically significant between-
group differences favouring the control group, meaning that it is safe to rule out entirely the 
possibility of any benefit of this particular BI with the brief training given to deliver it in routine 
practice. We interpret these two differences in secondary outcomes within the larger context 
of no difference between the groups. This study has direct implications for decision-making 
on NHS policy and practice, against the background of the developing public health role and 
remit of community pharmacies. Thus detailed consideration of the specific features of study 
design and internal and external validity of these findings is warranted. 
 
This trial was implemented in accordance with a published study protocol (15) and we are 
confident that recruitment, randomisation, blinding, data collection and analysis were 
rigorously conducted. Allocation sequence generation was unbiased, and there was no 
evidence of problems with allocation concealment, serving high internal validity. Blinding of 
participants to group allocation was not possible in this study, and participants gave fully 
informed consent. This raises the possibility of some heightened potential for performance 
bias and for unintended differences between the groups resulting from participant reactivity 
to study conditions including allocation (31). Moreover all participants received AUDIT score 
feedback indicating that they were hazardous or harmful drinkers for eligibility purposes, so 
raising the possibility of behaviour change in response to feedback and/or having attention 
drawn to alcohol consumption through study participation (32-34). Data collection and 
analysis were undertaken by researchers who were fully blinded to group allocation. The 
parsimonious approach taken to outcome evaluation avoided selective outcome reporting, 
and attrition bias would have to be implausibly extreme to impact on the study’s findings. A 
14 
 
two sided power calculation assuming 20% attrition (as observed) would require 220 
participants per group (440 in total) to provide 80% power to detect an effect of 0.3 SD and 
increasing the sample size to this level would not alter the conclusions drawn. The findings 
were highly consistent across outcomes and methods used, whether they originated from 
the unadjusted, adjusted or bootstrap models, or from the sensitivity analyses. For these 
reasons, we judge our findings not to be vulnerable to conventionally understood forms of 
bias. 
 
This study was undertaken in the context of routine service provision. This highly naturalistic 
study context is a substantial strength of the study, but also entails some weaknesses. 
Almost half of all pharmacists (n=17) in one London borough volunteered to participate, 
which compares very favourably with participation rates in BI trials in primary care. The 
pharmacists received a total of 3.5 hours training on intervention delivery, involving 
communication skills training influenced by the perspective of motivational interviewing (35). 
Whilst the BI intervention followed a structured protocol, some variability between 
pharmacists in their skills in engaging with participants should be expected, though no 
differences in outcomes were observed (data not reported).   
 
There have been few process studies of alcohol BI and consequently there is limited 
understanding of the active ingredients of BI (36, 37). It is therefore difficult to appreciate 
how specific this null finding is to the particular intervention evaluated here. The BI evaluated 
here was certainly not motivational interviewing, but rather followed a structured protocol 
influenced by this approach delivered in a 10 minute discussion. It is highly likely that the 
pharmacists were under-trained in BI, and it is a study limitation that the naturalistic context 
precluded audio-recording. We do not interpret reductions over time as providing evidence 
that both groups have benefitted, as change scores are inappropriate for effectiveness 
inferences for many reasons (38). 
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Limited training of healthcare practitioners in routine practice has also affected the results of 
other NHS effectiveness trials. One hour training was provided to deliver brief structured 
alcohol advice within the SIPS primary care trial, which failed to demonstrate superiority over 
leaflet and very brief feedback; similar to the control condition in the present study (39). In 
PRE-EMPT GPs and Practice Nurses accessed largely online training for Behaviour Change 
Counselling for alcohol and other lifestyle issues, with limited skills acquisition, and little 
evidence of effectiveness (40). Recent NHS effectiveness trials across settings have largely 
failed to find benefit, in contrast to earlier primary care efficacy trials (41). It is also possible 
or likely that earlier studies were undertaken by highly motivated clinicians and researchers, 
potentially with allegiance effects (42), and as such may be more likely to be biased; this 
possibility is supported by the large effects of interventions studied in these early trials with 
challenging populations that have not since been replicated (43, 44). 
 
Our study demonstrates that the community pharmacy setting is conducive to the delivery of 
BI. Pre-existing relationships between the pharmacist and customers within a healthcare 
environment are characteristics shared with general practice, where this evidence-base for 
BI has been assiduously developed over a period of approximately 30 years (4). Although 
accrual of evidence of benefit has been problematic in very busy clinical settings such as 
Accident and Emergency departments(45), setting-specific barriers to the delivery of BI are 
not obvious in community pharmacies. Community pharmacies have been identified by 
policy makers as promising for the delivery of preventive healthcare (46), being located 
where people live, work and shop (47). There are around 12,000 pharmacies in England and 
it is estimated 1.8 million people visit pharmacies every day (9). The UK government 
supports expanding the range of services provided by community pharmacists (48). On the 
basis of these findings, however, extending services with little or no additional training or 
other preparation for the wider public health role is inadvisable for activities targeting 
drinking, and most likely for behaviour change more broadly.  
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Redesign of intervention content and more intensive efforts to help prepare community 
pharmacists to become more ready and able to fulfil the wider professional role they are 
willing to embrace are now required. Strategic consideration of workforce development 
issues is also needed, which entails systemic changes that extend well beyond the provision 
of training. Although decision-making about resource use should be based on effectiveness 
and cost-effectiveness data, there may also be a role for efficacy trials in establishing that 
effectiveness is possible in this setting.  
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Figure 1 Trial recruitment and retention  
 
  
Approached in pharmacy (n= 2361) 
Excluded (n= 1954): 
   Declined to participate or excluded following 
Stage 1 single question screen (n=1820) 
   Excluded following Stage 2 screen: 
o (AUDIT ≤ 7), (n=94) 
o (AUDIT ≥ 20), (n=38) 
Incomplete data (n=2) 
Lost to follow-up (n=37) (18%) 
Unable to be contacted (by phone, email or 
post) (n = 37)  
Allocated to intervention group (n=205) 
 Received allocated intervention (n=205) 
Lost to follow-up (n=46) (23%) 
Unable to be contacted (by phone, email or 
post) (n = 46)  
 
Allocated to control group (n=202) 
 Received allocated intervention (n=202) 
Allocation 
Follow-Up 
Randomised (n=407) 
Enrollment 
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Table 1 Baseline characteristics at randomisation. Values are numbers (%) unless stated otherwise 
Characteristics 
Intervention group 
(n = 205) 
Control group 
(n = 202) 
Total 
(n = 407) 
Place of residence:    
Hammersmith and Fulham 162 (79.0) 154 (76.2) 316 (77.6) 
Other London Borough 34 (16.6) 37 (18.3) 71 (17.4) 
Outside London 8 (3.9) 10 (5.0) 18 (4.4) 
Missing values 1 (0.5) 1 (0.5) 2 (0.5) 
Total  205 (50.4) 202 (49.6) 407 (100) 
    
Age (years) mean (SD), range 
 
39.6 (15.90), 18-74, 
(n = 192) 
40.5 (17.48), 18-92, 
(n = 194) 
40.0 (16.70), 18-92, 
(n = 386) 
Missing values 13 (6.3) 8 (4) 21 ( 10.3) 
Total  205 (50.4) 202 (49.6) 407 (100) 
    
Gender:     
Female 98 (47.8) 88 (43.6) 186 (45.7) 
Male 107 (52.2) 114 (56.4) 221 (54.3) 
Total  205 (50.4) 202 (49.6) 407 (100) 
    
Ethnicity:    
Asian british: any other asian background   3 (1.5) 2 (1.0) 5 (1.2) 
Asian british: Indian  5 (2.4) 10 (5.0) 15 (3.7) 
Asian british: Pakistani 0 (0.0) 2 (1.0) 2 (0.5) 
    
Black british: any other black background  2 (1.0) 1 (0.5) 3 (0.7) 
Black british: African 6 (2.9) 8 (4.0) 14 (3.4) 
Black british: Caribbean 11  (5.4) 12 (5.9) 23 (5.7) 
    
Mixed: any other mixed background   2 (1.0) 2 (1.0) 4 (1.0) 
Mixed: white and asian  1 (0.5) 2 (1.0) 3 (0.7) 
Mixed: white and black African 1 (0.5) 2 (1.0) 3 (0.7) 
Mixed: white and black Caribbean 1 (0.5) 2 (1.0) 3 (0.7) 
    
Not stated  0 (0.0) 2 (1.0) 2 (0.5) 
    
Other ethnic groups:any other ethnic groups   3 (1.5) 0 (0.0) 3 (0.7) 
Other ethnic groups: Chinese  4 (2.0) 0 (0.0) 4 (1.0) 
    
White: any other white background  30 (14.6) 35 (17.3) 65 (16.0) 
White: British  117 (57.1) 102 (50.5) 219 (53.8) 
White: Irish  6 (2.9) 12 (5.9) 18 (4.4) 
    
Missing values 13 (6.3) 8 (4.0) 21 (5.2) 
Total  205 (50.4) 202 (49.6) 407 (100) 
    
Continuing education after age 16:    
Yes 159 (77.6) 154 (76.2) 313 (76.9) 
No 33 (16.1) 40 (19.8) 73 (17.9) 
Missing values 13 (6.3) 8 (4.0) 21 (5.2) 
Total  205 (50.4) 202 (49.6) 407 (100) 
 
  
Table 1a Baseline characteristics of groups who were followed up.  
(Values are numbers (%) unless stated otherwise)  
Characteristics 
Intervention group 
(n = 168) 
Control group 
(n = 158) 
Total 
(n = 326) 
Place of residence:    
Hammersmith and Fulham 135 (80.4) 121 (76.6) 256 (78.5) 
Other London Borough 27 (16.1) 27 (17.1) 54 (16.6) 
Outside London 6 (3.6) 9 (5.7) 16 (4.9) 
Missing values 0 (0) 1 (0.6) 0 (0) 
Total  168 (51.5) 158 (48.5) 326 (100) 
    
Age (years), mean (SD), range 
 
41.1 (16.08), 18-74, 
(n = 157) 
43.2 (18.09), 18-92, 
(n = 150) 
42.1 (17.09), 18-92, 
(n = 307) 
Missing values 11 (6.5) 8 (5.1) 19 ( 5.8) 
Total  168 (51.5) 158 (48.5) 326 (100) 
    
Gender:     
Female 81 (48.2) 63 (39.9) 144 (44.2) 
Male 87 (51.8) 95 (60.1) 182 (55.8) 
Total  168 (51.5) 158 (48.5) 326 (100) 
    
Ethnicity:    
Asian british: any other asian background   3 (1.8) 2 (1.3) 5 (1.5) 
Asian british: Indian  4 (2.4) 7 (4.4) 11 (3.4) 
Asian british: Pakistani 0 (0.0) 2 (1.3) 2 (0.6) 
    
Black british: any other black background  2 (1.2) 1 (0.6) 3 (0.9) 
Black british: African 5 (3.0) 6 (3.8) 11 (3.4) 
Black british: Caribbean 8 (4.8) 10 (6.3) 18 (5.5) 
    
Mixed: any other mixed background   2 (1.2) 1 (0.6) 3 (0.9) 
Mixed: white and asian  1 (0.6) 2 (1.3) 3 (0.9) 
Mixed: white and black African 1 (0.6) 1 (0.6) 2 (0.6) 
Mixed: white and black Caribbean 1 (0.6) 1 (0.6) 2 (0.6) 
    
Not stated  0 (0.0) 1 (0.6) 1 (0.3) 
    
Other ethnic groups:any other ethnic groups   2 (1.2) 0 (0.0) 2 (0.6) 
Other ethnic groups: Chinese  4 (2.4) 0 (0.0) 4 (1.2) 
    
White: any other white background  23 (13.7) 28 (17.7) 51 (15.6) 
White: British  97 (57.7) 80 (50.6) 177 (54.3) 
White: Irish  4 (2.4) 8 (5.1) 12 (3.7) 
    
Missing data 11 (6.5) 8 (5.1) 19 (5.8) 
Total  168 (51.5) 158 (48.5) 326 (100) 
    
Continuing education after age 16:    
Yes 129 (76.7) 119 (75.3) 248 (76.1) 
No 28 (16.7) 31 (19.6) 59 (18.1) 
Missing data 11 (6.5) 8 (5.1) 19 (5.8) 
Total  168 (51.5) 158 (48.5) 326 (100) 
 
  
Table 1b Demographic /professional backgrounds of pharmacists (n = 17) 
Characteristics No (%) 
Gender 
Female 
Male  
 
4 (24%) 
13 (77%) 
 
Mean years (± SD) 
Age a  
Registered as a pharmacist b 
Practised as a community pharmacist b 
Worked as a pharmacist in current pharmacy b 
 
 
42 (± 11.7)  
18 (± 11.0)  
17 (± 11.2)  
8 (± 6.6) 
 
Current post a 
Employee pharmacist 
Locum pharmacist 
Pharmacy manager 
Pharmacy owner 
 
 
6 (38%) 
1 (16%) 
2 (13%) 
7 (44%) 
 
Mean hours of training undertaken since (± SD) 
registering as a pharmacist 
Hours of alcohol misuse training a 
Hours of drug misuse training a 
Hours of smoking cessation training a 
 
 
 
3 (± 3.1) 
21 (± 16.2) 
25 (± 15.8) 
 
Had heard of BI prior to the study? a 
Yes 
No 
 
4 (25%) 
12 (75%) 
 
Provided BI to service users prior to the study? a 
Yes  
No 
 
0 (0%) 
16 (100%) 
 
Attended evening additional follow-up training 
session 
Attended training  
Not attended training 
 
 
 
10 (59%) 
7 (41%) 
a Missing data for 1 pharmacist. 
b Missing data for 2 pharmacists. 
 
  
Table 1c Characteristics of pharmacies (n = 16) 
Characteristics Number of study sites 
(%) 
 
Site type a 
Independent Chemist 
Multiple Chemist 
 
 
 
10 (63) 
6 (38) 
 
Site Location  
High street 
Housing Estate 
Shopping centre 
Doctor’s surgery 
 
 
 
11 (69) 
1 (6) 
3 (19) 
1 (6) 
 
Average number of NHS prescription 
items dispensed per site per day b 
51 – 100 
101 – 150 
151 – 200 
201 – 250 
251 – 300 
301 – 350 
 
 
 
 
3 (19) 
2 (13) 
3 (19) 
3 (19) 
1 (6) 
2 (13) 
 
a   Site type: ‘Independent Chemist’, operates retail pharmacy 
businesses from 9 or less premises. ‘Multiple Chemist’, operates 
retail pharmacy businesses from more than 9 premises.1 
b   Pharmacists at two sites declined to respond. 
 
1 Pharmaceutical Services Negotiating Committee. Pharmaceutical Services Negotiating Committee 
Constitution.2011 
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Table 2: All trial outcomes 
Values are means/differences to baseline/between group differences/odds ratio with 95% confidence intervals and P value 
 
 
Intervention group (n:BL=205, FU=168) 
Control group 
(n:BL=202,FU=158) 
Between group differences, P value 
Primary outcomes 
 
Overall Score Mean (SD) Difference to baseline† Mean (SD) Difference to baseline† Unadjusted‡ Adjusted& 
Baseline 11.93 (3.24) n/a 11.53 (3.19) n/a n/a n/a 
Follow-up 11.80 (5.88) -0.11 (-0.82 to 0.61), 0.76 10.77 (5.54) -0.74 (-1.47 to 0.00), 0.049 -0.63 (-1.69 to 0.43), 0.24 -0.57 (-1.59 to 0.45), 0.28 
       Overall Score < 8 at follow-up % ˂ 8. (No ˂ 8) % ˂ 8. (No ˂ 8) Unadjusted Odds Ratio Adjusted Odds  Ratio 
 22.6 (38)  26.6 (42)  0.80b (0.48 to 1.34), 0.40 0.87c (0.50 to 1.51), 0.61 
       
Secondary outcomes       
       
Consumption sub-scale: 
Baseline 8.29 (1.55) n/a 8.02 (1.53) n/a n/a n/a 
Follow-up 7.58 (2.31) -0.75 (-1.08 to -0.41), <0.001 7.37 (2.52) -0.69 (-1.03 to  -0.35), <0.001 -0.05 (-0.53 to 0.43), 0.84 -0.05 (-0.54 to 0.44), 0.85 
Dependence sub-scale: 
Baseline 1.04 (1.35) n/a 1.05 (1.34) n/a n/a n/a 
Follow-up 1.23 (2.13) 0.22 (-0.05 to 0.50), 0.11 0.75 (1.54) -0.29 (-0.57 to -0.01), 0.041 -0.51 (-0.89 to -0.13),0.008 -0.46 (-0.82 to -0.09),0.014 
Problem use sub-scale: 
Baseline 2.60 (2.14) n/a 2.46 (2.19) n/a n/a n/a 
Follow-up 2.99 (2.82) 0.42 (0.03 to 0.80), 0.033 2.65 (2.97) 0.26 (-0.13 to 0.65), 0.20 -0.18 (-0.72 to 0.36), 0.52 -0.13 (-0.66 to 0.41), 0.64 
General Health (EQ-5D)a at 
follow-up: 1.28 (0.35) n/a 1.20 (0.32) n/a -0.09 (-0.16 to -0.01), 0.019 -0.09 (-0.16 to -0.02),0.013 
       
† pharmacist and person (nested with pharmacist) random effects; effect of time (difference to baseline) nested within intervention/control 
‡ pharmacist random effect; adjusted for baseline score 
& pharmacist random effect; adjusted for baseline score, gender, age, ethnicity and education 
a EQ-5D General Health: mean of mobility, self-care, usual activities, pain-discomfort, anxiety-depression: general health; scoring (1 = no problem, 2 = some problems, 3 = severe problems/unable) 
b pharmacist random effect 
c pharmacist random effect adjusted for gender, age, ethnicity and education 
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CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 2-3 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 4-5 
2b Specific objectives or hypotheses 4-5 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 6 & 8 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons None 
Participants 4a Eligibility criteria for participants 7  
4b Settings and locations where the data were collected 7 & 9 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
9 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
9-10 
6b Any changes to trial outcomes after the trial commenced, with reasons n/a, None 
Sample size 7a How sample size was determined 6 
7b When applicable, explanation of any interim analyses and stopping guidelines n/a, None 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 8 
8b Type of randomisation; details of any restriction (such as blocking and block size) 8 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
8 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
8 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 8-9 
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assessing outcomes) and how 
11b If relevant, description of the similarity of interventions 9 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 10 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 10 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
19 
13b For each group, losses and exclusions after randomisation, together with reasons 11 & 18 
Recruitment 14a Dates defining the periods of recruitment and follow-up 6 
14b Why the trial ended or was stopped n/a 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 19 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
19 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
20 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended 20 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
11-12 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 12 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 14-16 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 15-16 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 13-16 
Other information 
 
Registration 23 Registration number and name of trial registry 1 
Protocol 24 Where the full trial protocol can be accessed, if available 6 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 17 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If 
relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal 
interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
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